ADAM9 Antibody (138537) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB, IP
• Clone: 138537
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

ADAM9 Antibody (138537) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human ADAM9 Ectodomain
  Accession # Q13443
• Specificity: Detects human ADAM9 Ectodomain in Western blots. In Western blots, approximately 10% cross-reactivity with the ectodomain of recombinant mouse ADAM9 is observed and no cross-reactivity with the ectodomain of recombinant human ADAM8, 9, 15, or 17
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ADAM9 Antibody (138537) [Alexa Fluor® 700]

• a disintegrin and metalloproteinase domain 9 (meltrin gamma)
• ADAM 9
• ADAM metallopeptidase domain 9 (meltrin gamma)
• ADAM metallopeptidase domain 9
• ADAM9
• Cellular disintegrin-related protein
• cone rod dystrophy 9
• CORD9
• disintegrin and metalloproteinase domain-containing protein 9
• EC 3.4.24
• EC 3.4.24.-
• MCMP
• MCMPMDC9KIAA0021Mltng
• MDC9
• Meltrin gamma
• Meltrin-gamma
• Metalloprotease/disintegrin/cysteine-rich protein 9
• MLTNG
• Myeloma cell metalloproteinase

Background

ADAM9, also known as MDC9 or meltrin gamma , is a member of the ADAM family that contains a disintegrin and metalloprotease-like domain (1). Like other membrane-anchored ADAMs, ADAM9 consists of a pro domain with a cysteine switch and furin cleavage sequence, a catalytic domain with the zinc-binding site and Met-turn expected for reprolysins, a disintegrin-like domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and the cytoplasmic domain. ADAM9 is able to cleave peptides corresponding to cleavage sites of tumor necrosis factor-alpha (TNF-alpha ), the p75 TNF receptor, the beta -amyloid protein precursor, and the c-kit ligand-1, implying that it may participate in shedding of these membrane proteins (2). In fact, ADAM9 has been shown to shed membrane-anchored heparin-binding EGF-like growth factor (3). In addition, it also cleaves oxidized insulin beta -chain and fibronectin (2,4). Besides its catalytic activity, ADAM9 functions as an adhesion molecule through binding of its disintegrin domain to integrins such as alpha _v beta ₅ and alpha ₆ beta ₁ (5, 6). The cytoplasmic domain of ADAM9 interacts with Src homology 3
(SH3)‑containing proteins and protein kinase C, and may mediate different signaling pathways (3, 7). ADAM9 is widely expressed in tissues (8).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.